一、关于公司《2023 年半年度募集资金存放与使用情况专项报告》的独立 意见 青岛海泰新光科技股份有限公司 独立董事对第三届董事会第十四次会议相关事项的 独立意见 根据《青岛海泰新光科技股份有限公司章程》和有关法律法规的规定，我们 作为青岛海泰新光科技股份有限公司（以下简称"公司"）的独立董事，对第三 届董事会第十四次会议的议案进行了认真审议，对需要独立董事发表独立意见的 相关议案发表独立意见如下： （本页无正文，为《青岛海泰新光科技股份有限公司独立董事关于公司第三届董 事会第十四次会议相关事项的独立意见》的签署页之三） 经核查，我们认为：公司2023年度半年度募集资金存放和实际使用符合《上 市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所上市公司募集资金管理办法（2013年修订）》等相关法律法规和规范性 文件的规定。公司所披露的募集资金存放和使用情况信息与实际情况相符，不存 在变相改变募集资金用途、违规存放与使用募集资金的情形，也不存在损害公司 及股东,尤其是中小股东利益的情形。综上，我们同意关于公司《2023年半年度 募集资金存放与使用情况专项报告》的议案。 张自力 ZIL ...

证券代码：688677 证券简称：海泰新光 公告编号：2023-039 青岛海泰新光科技股份有限公司 关于公司募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》、《上海证券交易所科创板股票上市规则》和《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，青岛海 泰新光科技股份有限公司（以下简称"公司"）董事会对 2023 年半年度募集资 金存放与实际使用情况专项报告说明如下： 一、募集资金基本情况 （一）经上海证券交易所科创板股票上市委员会 2020 年 9 月 29 日审核同意， 并经中国证券监督管理委员会 2021 年 1 月 12 日《关于同意青岛海泰新光科技股 份有限公司首次公开发行股票注册的批复》（证监许可[2021]90 号）核准，同 意本公司公开发行人民币普通股 21,780,000 股，发行价格为人民币 35.76 元/ 股。募集资金总额为人民币 77 ...

国泰君安证券股份有限公司 关于青岛海泰新光科技股份有限公司 2023 年半年度持续督导跟踪报告 国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作为青岛 海泰新光科技股份有限公司（以下简称"海泰新光"或"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证 券交易所科创板股票上市规则》、《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关规定，负责海泰新光上市后的持续督导工作，并出具本 持续督导跟踪报告。 | 一、持续督导工作情况 | | --- | | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导业务管理制 | 保荐机构已建立健全并有效执行持 续督导工作制度，并制作了相应的 | | 1 | 度；制作并保存持续督导工作底稿 | | | | | 持续督导工作底稿 | | 2 | 建立健全保荐代表人工作制度，明确保荐代 表人的工作要求和职责，建立有效的考核、 | 保荐机构已建立健全并有效执行保 | | | | 荐代表人工作制度 | | | 激励和约束机制 在持续督导期 ...

股票代码：688677 股票简称：海泰新光 公告编号：2023-037 青岛海泰新光科技股份有限公司 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 22 日(星期二) 至 08 月 28 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@novelbeam.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 青岛海泰新光科技股份有限公司（以下简称"公司"）将于 2023 年 8 月 29 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上半年经营成果、财务状况，公司计划于 2023 年 08 月 29 日下午 16:00-17:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、回购股份的基本情况 公司于 2023 年 6 月 15 日召开第三届董事会第十三次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"）， 同意公司以自有资金通过上海证券交易所交易系统以集中竞价交易方式回购公 司已发行的部分人民币普通股股票。回购的股份将在未来适宜时机全部用于员工 持股计划或股权激励，回购价格不超过 90 元/股（含），回购资金总额不低于人 民币 3,000 万元（含），不超过人民币 6,000 万元（含），回购期限自公司董事 会审议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2023 年 6 月 16 日在上海证券交易所网站（www.sse.com.cm）上披露的《青岛海泰新光科技 股份有限公司关于以集中竞价交易方式回购股份方案的公告》（公告编号： 2023-027）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，现将公司回 ...

Financial Performance - The company's operating revenue for 2022 reached ¥476,821,312.39, representing a year-on-year increase of 53.97%[24]. - Net profit attributable to shareholders increased by 55.07% to ¥182,569,601.64, while the net profit excluding non-recurring gains and losses rose by 79.44% to ¥168,680,318.38[24][27]. - The cash flow from operating activities remained stable, with a net amount of ¥104,375,771.45, showing a slight increase of 0.36% compared to the previous year[24][27]. - Total assets grew by 17.92% to ¥1,393,534,642.98, and net assets attributable to shareholders increased by 11.75% to ¥1,219,243,201.94[24][27]. - Basic earnings per share rose to ¥2.10, reflecting a 48.94% increase from the previous year[25]. - The company's operating income for the fourth quarter was 137,148,352.30 RMB, while the net profit attributable to shareholders was 42,692,243.69 RMB, indicating a stable performance despite fluctuations in net profit due to factors such as share-based payments and exchange rate losses[30][31]. Dividend and Capital Structure - The company plans to distribute a cash dividend of RMB 8.00 per 10 shares, totaling RMB 69,314,761.60 (including tax) based on the remaining shares after buybacks[5]. - The company intends to increase its capital reserve by issuing 4 additional shares for every 10 shares held, resulting in an increase of 34,657,381 shares, raising the total share capital to 121,637,381 shares[5]. - The company has not experienced any changes in its total share capital from the announcement date to the equity distribution registration date[6]. Audit and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for external guarantees[9]. - The company has not disclosed any special arrangements for corporate governance[9]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors[8]. Research and Development - The company's R&D expenditure accounted for 12.56% of operating revenue, a decrease of 0.79 percentage points compared to 2021[25]. - Research and development investment in 2022 was 59.90 million yuan, a 44.88% increase from the previous year, constituting 12.56% of operating revenue[40]. - The company applied for 42 new patents and obtained 33 new patents during the reporting period[118]. - The company has a cumulative total of 156 patent applications, with 96 patents granted, reflecting its commitment to innovation[119]. - The company has developed a dual-channel 3D fluorescence endoscope technology suitable for 10mm laparoscopic systems, enhancing surgical capabilities[115]. Market and Sales - The company achieved dual growth in both domestic and international markets while expanding its optical business and related products alongside the rapid growth of its medical endoscope business[38]. - The company plans to increase the promotion of its complete system products domestically, despite facing competition from established imported brands[136]. - The total sales revenue for the top five customers reached 375.19 million RMB, accounting for 78.69% of the annual sales total[157]. - Sales to Customer 1 amounted to 295.44 million RMB, representing 61.96% of the annual sales total, with a year-on-year increase of 67.41%[158]. Production and Supply Chain - The company has increased inventory to mitigate the impact of extended delivery times due to global supply chain disruptions[54]. - The company implements a supply chain management system that includes supplier grading and continuous evaluation to ensure quality[51]. - The production of medical endoscopes follows ISO 13485 standards, ensuring compliance with quality management requirements[54]. - The company has seen an increase in procurement from new suppliers due to increased production of new products[163]. Technological Innovation - The company has established four core technology platforms: optical technology, precision machinery technology, electronic technology, and digital image technology[76]. - The company has successfully implemented multi-spectral LED illumination technology in endoscope systems, which can also be extended to clinical diagnostic applications[81]. - The company has developed a leading fluorescence endoscope that integrates fluorescence technology with endoscopic technology, opening new applications in the medical field[74]. - The company is integrating deep learning-based intelligent image recognition technology into its next-generation intelligent surgical endoscope system[75]. Future Plans - The company plans to accelerate the development of medical endoscope series products to expand its existing product line[182]. - The company aims to enhance its competitive edge in fluorescence endoscope products by continuously upgrading existing models and developing new ones[184]. - The company is committed to strengthening talent development and improving employee cohesion through a competitive compensation system[192]. - The company will complete the registration and launch of the second generation 4K fluorescence endoscope imaging system and fog-free imaging system, establishing a nationwide distribution channel[194].

Financial Performance - The company's operating revenue for Q1 2023 reached ¥148,428,523.74, representing a year-on-year increase of 58.76%[4] - Net profit attributable to shareholders was ¥48,464,088.23, up 35.40% year-on-year, while the net profit excluding non-recurring gains and losses increased by 38.45%[6] - Total revenue for Q1 2023 reached RMB 148,428,523.74, a significant increase of 58.8% compared to RMB 93,489,632.76 in Q1 2022[20] - Net profit for Q1 2023 was RMB 47,706,648.48, representing a growth of 34.0% from RMB 35,609,101.09 in Q1 2022[21] - The company's total revenue for Q1 2023 was ¥62,700,194.25, a 96% increase from ¥32,019,026.46 in Q1 2022[26] - The net profit attributable to the parent company was ¥48,119,272.38, compared to ¥35,401,219.15 in the same period last year, reflecting a growth of approximately 36%[22] - The company reported a total profit of 33,289,165.08 RMB in Q1 2023, down from 39,629,682.06 RMB in Q1 2022, representing a decrease of about 16.5%[27] - The company’s net profit for Q1 2023 was 33,913,075.60 RMB, compared to 39,554,279.81 RMB in Q1 2022, marking a decrease of approximately 14.2%[27] Research and Development - The company's R&D investment totaled ¥17,142,509.37, marking a significant increase of 61.26% compared to the same period last year, accounting for 11.55% of operating revenue[5] - Research and development expenses increased to RMB 17,142,509.37 in Q1 2023, a rise of 61.5% compared to RMB 10,630,408.34 in Q1 2022[20] Cash Flow and Liquidity - Cash received from sales amounted to ¥144,082,100, an increase of 53.25% year-on-year, although net cash flow from operating activities decreased by 23.33%[6] - Cash inflow from operating activities totaled ¥154,311,431.44, up from ¥101,078,683.79 in Q1 2022, marking a 52.6% increase[22] - The net cash flow from operating activities was ¥17,993,727.64, down from ¥23,469,085.19 in the previous year, indicating a decrease of 23.5%[22] - The company reported a net cash outflow from investing activities of ¥84,405,259.84, an improvement from a net outflow of ¥427,691,546.92 in Q1 2022[22] - Cash and cash equivalents decreased to RMB 568,106,391.00 from RMB 636,150,039.18 at the end of 2022[19] - Cash and cash equivalents at the end of Q1 2023 totaled 302,366,859.53 RMB, down from 395,801,944.38 RMB at the beginning of the quarter[30] Expenses and Costs - The company's sales costs increased by 63.28%, primarily due to the rise in sales revenue[10] - Management expenses rose by 55.44%, driven by increased personnel costs and depreciation of fixed assets[10] - Operating costs for Q1 2023 amounted to RMB 91,055,804.33, up 71.1% from RMB 53,194,317.21 in the same period last year[20] - Cash paid for purchasing goods and services surged by 96.46% as the company continued to expand production and increase material reserves[11] - Cash paid for taxes increased by 204.17% due to higher sales revenue and the payment of deferred taxes from the previous year[11] - Tax expenses rose by 48.17% primarily due to increased sales and profits leading to higher corporate income tax provisions[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,404,531,032.78, a slight increase of 0.79% from the end of the previous year[5] - The company's total assets as of March 31, 2023, were RMB 1,404,531,032.78, up from RMB 1,393,534,642.98 at the end of 2022[19] - The total liabilities decreased to RMB 126,444,870.54 as of March 31, 2023, from RMB 171,048,771.88 at the end of 2022[19] - The company's total liabilities decreased to ¥121,864,630.85 from ¥181,857,440.84, a reduction of approximately 32.9%[25] - The equity attributable to shareholders increased to RMB 1,275,308,816.90 as of March 31, 2023, compared to RMB 1,219,243,201.94 at the end of 2022[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,080[13] - The company's basic and diluted earnings per share were both ¥0.56, reflecting a year-on-year increase of 36.59%[4] - Basic and diluted earnings per share increased to ¥0.56 from ¥0.41, representing a 36.6% rise year-over-year[22]

Financial Performance - The company's operating revenue for 2022 reached ¥476,821,312.39, representing a year-on-year increase of 53.97%[24]. - Net profit attributable to shareholders increased by 55.07% to ¥182,569,601.64, while the net profit after deducting non-recurring gains and losses rose by 79.44% to ¥168,680,318.38[24]. - The cash flow from operating activities remained stable, with a net amount of ¥104,375,771.45, showing a slight increase of 0.36% compared to the previous year[24]. - Total assets increased by 17.92% to ¥1,393,534,642.98, and net assets attributable to shareholders rose by 11.75% to ¥1,219,243,201.94[24]. - The basic earnings per share for 2022 was ¥2.10, reflecting a growth of 48.94% compared to the previous year[25]. - The company's operating income for the fourth quarter was 137,148,352.30 RMB, while the net profit attributable to shareholders was 42,692,243.69 RMB, indicating a stable profit despite fluctuations in operating income[30]. - The net profit attributable to shareholders for the third quarter was 60,007,924.16 RMB, reflecting strong performance in that period[30]. - The company reported a total revenue of 130.9 million RMB, with a net profit of 59.9 million RMB, reflecting a significant increase in performance compared to the previous year[125]. Research and Development - The company's R&D investment as a percentage of operating revenue was 12.56%, a decrease of 0.79 percentage points from the previous year[25]. - The company's R&D investment in 2022 was 59.90 million yuan, a 44.88% increase from 41.34 million yuan in the previous year, accounting for 12.56% of operating revenue[40]. - The company has established a clear R&D project mechanism to ensure the continuous development of innovative products and technologies[48]. - The company has developed a non-contact, high-precision palm vein recognition identity authentication product with a recognition rate of 99.99% and a false recognition rate of only 0.00001%[66]. - The company has filed 42 new patent applications and received 33 new patent grants during the reporting period, indicating strong innovation activity[118]. - The company has established a comprehensive R&D team with expertise in optics, precision machinery, automation, and software, aiming to improve overall human resource quality[193]. Product Development and Innovation - The first-generation 4K fluorescence imaging system received product registration and was launched for clinical use during the reporting period, laying the foundation for market sales and product iteration[38]. - The company is expanding its product line in the medical optical imaging field, including 4K fluorescence/white light laparoscopes and various endoscopes, with ongoing development of multiple products to enhance market presence[42]. - The company has successfully developed a remote rehabilitation device that received registration certification on March 11, 2023, indicating progress in telemedicine[125]. - The company is actively developing 4K ultra-high-definition endoscope products across various departments, with the 4K ultra-high-definition fluorescence laparoscope already registered[184]. - The company is focusing on the development of consumer-grade palm vein modules to meet diverse customer needs and promote the application of palm vein technology[194]. Market Expansion and Sales - The company achieved dual growth in both domestic and international markets while expanding its optical business and related products alongside the medical endoscope business[38]. - The company plans to enhance its marketing network and information technology projects to improve market share and sales capabilities in the domestic market[136]. - The company has established 7 marketing network centers in Shandong province to cover most medical institutions in the area[136]. - The company is exploring the establishment of final assembly and repair lines in the United States to mitigate international trade risks[141]. - Domestic sales revenue increased by 77.86%, contributing to a 3.18% rise in its share of total revenue, driven by the expansion of the domestic marketing system[150]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for external guarantees[9]. - The company has not experienced any instances where more than half of the board members could not guarantee the accuracy and completeness of the annual report[9]. - The company has established a comprehensive quality management system, achieving certifications from NMPA, FDA, CE, MFDS, and INMETRO, ensuring compliance with global quality standards[134]. Financial Management - The company has a dependency on a limited number of customers, with one customer accounting for over 50% of total sales, indicating a risk in customer concentration[159]. - The accounts receivable increased by 83.06% to 1.14 billion RMB due to higher sales revenue during the reporting period[167]. - Inventory rose by 108.66% to 138.01 million RMB as the company increased material procurement reserves in response to market conditions and expanded production scale[169]. - The company reported a significant increase in prepayments, which rose by 145.78% to 66.42 million RMB, attributed to material procurement and software development[167]. - The company reported a 200.06% increase in taxes payable, amounting to RMB 21,568,078.86, primarily due to increased profits and corporate income tax obligations[170]. Strategic Partnerships - The company has established a long-term partnership with US medical device giant Stryker, contributing to the development of core optical components for endoscope systems[64]. - The company signed a major sales contract with Stryker, with a total contract value of ¥385,982,657.13, of which ¥108,618,939.57 has been fulfilled[154]. - The company is actively pursuing partnerships with hospitals and research institutions to enhance R&D capabilities and accelerate product development[49]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[4]. - The company is actively managing risks related to international trade and currency fluctuations to protect its business operations[140].

股票代码：688677 股票简称：海泰新光 公告编号：2023-014 青岛海泰新光科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心音频直播和网络互动 投资者可于 2023 年 04 月 14 日(星期五) 至 04 月 20 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@novelbeam.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 青岛海泰新光科技股份有限公司（以下简称"公司"）将于 2023 年 4 月 21 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 04 月 21 日 下午 15:00-16:30 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本 ...

海泰新光 2022 年 4 月份投资者调研记录 Q：疫情对物流、人员、上游供应链、出口是否有影响？公司是否有针对疫情方面的应对策 略？ 这两年来疫情一直不停反复，针对主要的影响因素，公司也做了一些相应的准备，如： （1）去年开始供应链就已面临困难，采购周期变长，公司在去年开始已对重要的生产材料 加大了库存量，以减少上游供应链的影响；（2）从 2020 年疫情开始后，国际物流的时间周 期加长、发运量减少，针对这一情况，公司加快了出口发运的时间频次，采用多批次、小批 量的方法进行发运。 今年以来，疫情在全国各地反复出现，其中 3 月中旬到 3 月底这半个月时间的青岛疫情 比较严重，也对公司的生产管理造成了一定的影响。主要包括：（1）由于疫情管控需要， 对一些小区进行了阶段性的封闭管理，公司有部分员工不能按时到公司上班，这种情况持续 了 1-2 周。公司通过部分员工驻厂和加班的方法，克服了短期的人员缺失困难，保障了生产 的正常运行。（2）物流时间加长，包括国内和国外物流，造成公司进料和出货周期加长， 公司前期的材料库存和发运策略降低了这一不利影响。（3）公司正处于产能扩充期，青岛 疫情影响厂房建设、设备安装和新招聘 ...